Serial changes of the serum macrophage colony-stimulating factor level after cytoreductive chemotherapy.
To investigate the physiologic role of macrophage colony-stimulating factor (M-CSF) in hematological recovery from bone marrow hypoplasia, we used an enzyme-linked immunosorbent assay to measure serial changes of the serum M-CSF level during 25 intensification chemotherapy courses given to seven patients with acute non-lymphocytic leukemia who were in complete remission. Three M-CSF peaks were observed during therapy: the first peak was during or just after chemotherapy, the second peak was around the leukocyte nadir, and the third peak coincided with a rapid increase in the monocyte count. We could find no significant correlation between the height of the second peak and the time from the initiation of therapy to hematological recovery. On the other hand, there was a significant positive correlation between the height of the second peak and the interval from the last day of chemotherapy to the peak (r = 0.62, p = 0.001), and there was a significant negative correlation between the peak height and the time from the peak until hematological recovery (defined as a neutrophil count of over 500/microliters (r = -0.63, p = 0.001) and a leukocyte count of over 1,000/microliters (r = 0.55, p = 0.008)). However, we found only a weak correlation between the peak height and monocyte recovery. These data suggest that increased M-CSF levels lead to the stimulation of granulocyte progenitors, and that we can predict the time of neutrophil recovery by monitoring the serum M-CSF level and finding its peak.
Kimura
F
F
Department of Internal Medicine III, National Defense Medical College, Saitama, Japan.
Takemura
Y
Y
Ohtsuki
T
T
Mizukami
H
H
Takagi
S
S
Yamamoto
K
K
Nagata
N
N
Motoyoshi
K
K
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004797:Enzyme-Linked Immunosorbent Assay; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood* / Q000188:drug therapy; D007958:Leukocyte Count; D007970:Leukopenia / Q000097:blood* / Q000139:chemically induced; D016173:Macrophage Colony-Stimulating Factor / Q000097:blood* / Q000502:physiology; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D011237:Predictive Value of Tests; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D014751:Vindesine / Q000008:administration & dosage / Q000009:adverse effects
D003561:Cytarabine; D005047:Etoposide; D016173:Macrophage Colony-Stimulating Factor; C015019:enocitabine; D008942:Mitoxantrone; D015122:Mercaptopurine; D014751:Vindesine; D011241:Prednisone; D003630:Daunorubicin